title: Erythropoietin upregulates the expression of its own receptor in TF-1 cell line.
abstract: In the erythroleukemia cell line TF-1, recombinant human erythropoietin (rHEpo), but not c-kit ligand, enhanced the number of cells expressing the erythropoietin receptor (EpoR), as measured by flow-cytometric analysis of binding of the biotin-labeled Epo. Moreover, 125I-Epo binding and Scatchard analyses, indicated that TF-1 cells, maintained in standard conditions with IL-3, and those stimulated with c-kit ligand, bear a single class of EpoR. On the other hand, cells cultured in the presence of rHEpo had a higher number of receptors than IL-3 or c-kit ligand-stimulated cells, and had two binding sites with different affinities for the ligand. EpoR mRNA expression was higher in cells exposed to rHEpo than in IL-3 or c-kit-stimulated cells. This difference may have been dependent on either a higher level of transcription or an increased stability of mRNA. The observed changes of EpoR in rHEpo-stimulated TF-1 cell line could cooperate, together with the alteration of the gene (3' end deletion), in the occurrence of the erythroleukemic process. Changes induced in EpoR by rHEpo were not accompanied by an increase in the expression of glycophorin A or globin chain mRNAs. This may suggest that rHEpo is unable to induce erythroid differentiation in TF-1 cells. The results also indicate that this cell line could be a model for the investigation of the role of transcription factor(s) in the expression of EpoR, and for the study of the mechanism(s) underlying the changes in the number and affinity of the cell receptors.
authors.affiliation: Division of Hematology, Policlinico Careggi, Florence, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Grossi
authors.forename: A M
authors.initials: AM
authors.lastname: Vannucchi
authors.forename: P
authors.initials: P
authors.lastname: Bacci
authors.forename: R
authors.initials: R
authors.lastname: Caporale
authors.forename: G
authors.initials: G
authors.lastname: Cappelli
authors.forename: G
authors.initials: G
authors.lastname: Visconti
authors.forename: G
authors.initials: G
authors.lastname: Pagliai
authors.forename: P R
authors.initials: PR
authors.lastname: Ferrini
mesh_terms: D004921:Erythropoietin / Q000378:metabolism / Q000494:pharmacology*; D005434:Flow Cytometry; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000378:metabolism* / Q000473:pathology; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis; D017467:Receptors, Erythropoietin / Q000096:biosynthesis*; D011994:Recombinant Proteins; D019089:Stem Cell Factor / Q000378:metabolism / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D015854:Up-Regulation
chemical_list: D012333:RNA, Messenger; D017467:Receptors, Erythropoietin; D011994:Recombinant Proteins; D019089:Stem Cell Factor; D004921:Erythropoietin